US equities |
MU $1,045.56 ▲+0.00% INTC $112.50 ▲+0.00% NVDA $239.24 ▲+0.00% SNDK $1,660.46 ▲+0.00% SPCX $171.92 ▲+0.00% AMD $649.42 ▲+0.00% MRVL $287.01 ▲+0.00% AVGO $375.81 ▲+0.00%
FinancialContent

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

5.840 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Clearmind Medicine Inc. Scores Milestone Patent Issuance To Expedite And Protect Psychedelic-Based Treatment For AUD ($CMND)
Via AB Newswire
Topics Intellectual Property
News headline image
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani
Via ACCESSWIRE
News headline image
Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Inc. Is Disrupting The Pharmaceuticals Landscape; First-To-Market Psychedelic-Based Treatment For AUD In Its Crosshairs ($CMND)
Via AB Newswire
News headline image
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More ↗
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
Via Benzinga
News headline image
Israeli Psychedelics Biotech Shares Latest Advancements, Moves Forward With Addictions Treatment ↗
Psychedelics company Clearmind Medicine Inc. (NASDAQ: CMND) aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for... 
Via Benzinga
News headline image
Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
News headline image
Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! 
Via InvestorPlace
News headline image
Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More ↗
LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon 
Via Benzinga
News headline image
Clearmind Gears Up For Clinical Trial To Test Drug That Treats Alcohol Addiction ↗
Israeli psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) is commencing the production of its proprietary drug candidate based on the MEAI molecule. 
Via Benzinga
News headline image
Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More ↗
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
Via Benzinga
News headline image
Aegis Capital Corp. Acted as Sole Bookrunner on a $7.5 Million Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ: CMND)
Via ACCESSWIRE
News headline image
Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split ↗
Psychedelics biotech firm Clearmind Medicine Inc. 
Via Benzinga
News headline image
Dow Surges More Than 300 Points After Producer Prices Increase Less Than Expected ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >